<DOC>
	<DOCNO>NCT00881504</DOCNO>
	<brief_summary>This study patient biliary tract cancer spread candidate surgical resection . The purpose research determine bevacizumab safely administer Modified FOLFOX 6 find effect , good and/or bad , type treatment biliary cancer . In study , combination chemotherapy , Modified FOLFOX6 biologic agent , bevacizumab test . Subjects study receive chemotherapy bevacizumab every 2 week disease get bad unable tolerate treatment .</brief_summary>
	<brief_title>A Study FOLFOX6 With Bevacizumab Biliary System Carcinoma</brief_title>
	<detailed_description>This single-center , open label , single-arm study patient previously untreated unresectable biliary tract cancer . This trial follow Simon 's two-stage optimal design . For first stage , 9 patient accrue . If none 9 patient controlled disease mFOLFOX6 combination bevacizumab , combination reject trial stopped . However , least 1 patient 9 ( 11 % ) respond treatment first stage , additional 15 patient enter second stage , total 24 patient phase II study . If 3 ( 13 % ) patient respond therapy , combination consider investigation .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis nonresectable adenocarcinoma biliary tract , include carcinoma gallbladder , intrahepatic extrahepatic biliary tract , ampullary cancer Measurable evaluable disease Locally advance disease inoperable ot patient disease recurrence curative surgical attempt Ambulatory ECOG performance status 01 Adequate organ marrow function Must agree avoid pregnancy prior study entry throughout duration study participation Ability understand willingness sign write informed consent document Any prior chemotherapy Patients receive investigational agent Patients receive radiotherapy 25 % bone marrow reason Peripheral neuropathy &gt; /= 2 Known brain metastasis , uncontrolled seizure disorder , encephalitis Prior history hypertensive crisis hypertensive encephalopathy , uncontrolled hypertension , unstable angina , congestive heart failure New York Heart Association ( NYHA ) class 2 great , leave ventricular ejection fraction le 50 % , clinically significant vascular disease , serious cardiac arrhythmia require medication , cardiomyopathy History myocardial infarction , unstable angina stroke/transient ischemic attack ( TIA ) within 6 month History allergy oxaliplatin , 5fluoruracil ( 5FU ) , Leucovorin , Bevacizumab History intraabdominal abscess within 4 week study entry , abdominal fistula , gastrointestinal perforation , active peptic ulcer disease , inflammatory bowel disease Evidence bleed diathesis coagulopathy Serious nonhealing wound , ulcer , bone fracture Major surgical procedure , open biopsy , significant traumatic injury within 4 week study entry anticipation need major surgery course study Minor surgical procedure core biopsy within 7 day enrollment , chemotherapy port placement within 24 hour Patients fulldose anticoagulant range international normalize ratio ( INR ) active bleeding Concurrent malignancy unless subject curatively treated disease free &gt; /= 2 year cancer nonmelanoma skin cancer early cervical cancer Uncontrolled intercurrent illness include , limited , ongoing active infection psychiatric illness/social situation would limit compliance study requirement Known HIV Hepatitis B C Life expectancy le 12 week Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Biliary</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>